How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics, Inc. (NASDAQ:CEMI) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.05. The company earned $12.06 million during the quarter. Chembio Diagnostics had a negative net margin of 47.03% and a negative trailing twelve-month return on equity of 113.57%. During the same quarter in the prior year, the company earned ($0.28) EPS.

What other stocks do shareholders of Chembio Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC) , Calumet Specialty Products Partners (CLMT) , Two Harbors Investment (TWO) , BlackRock Capital Investment (BKCC) , NovoCure (NVCR) , Viper Energy (VNOM) , Summit Midstream Partners (SMLP) , Washington Prime Group (WPG) , Roper Technologies (ROP) and ReWalk Robotics (RWLK) .

NASDAQ:CEMI

Chembio Diagnostics (CEMI) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free CEMI Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.45
▼
$0.46
50-Day Range: $0.33
▼
$0.46
52-Week Range: $0.19
▼
$1.24

Volume: 351,642 shs
Average Volume: 661,416 shs
Market Capitalization: $16.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Chembio Diagnostics alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Chembio Diagnostics Stock (NASDAQ:CEMI)

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

CEMI Stock News Headlines

April 17, 2024 | finance.yahoo.com

ANY LAB TEST NOW Forms Strategic Partnership with Chembio

November 2, 2023 | morningstar.com

Quest Diagnostics Inc DGX

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

July 24, 2023 | marketwatch.com

Qualigen Therapeutics Sells FastPack Diagnostics Business to Chembio

April 27, 2023 | finance.yahoo.com

Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

April 27, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Laboratory (LH), Arbutus Biopharma (ABUS) and Chembio Diagnostics (CEMI)

April 20, 2023 | benzinga.com

Shareholder Alert: Ademi LLP investigates whether Chembio Diagnostics, Inc. has obtained a Fair Price in its transaction with Biosynex

April 19, 2023 | finance.yahoo.com

Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 14, 2023 | msn.com

Chembio Diagnostics And 2 Other Stocks Under $1 Insiders Are Aggressively Buying

April 10, 2023 | finance.yahoo.com

Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023

April 3, 2023 | finance.yahoo.com

Chembio’s CEO Letter to Stockholders

March 21, 2023 | finance.yahoo.com

Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023

March 15, 2023 | finance.yahoo.com

Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.

March 15, 2023 | finance.yahoo.com

Chembio Announces Letter to Stockholders Regarding Tender Offer

February 24, 2023 | finance.yahoo.com

Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System

February 8, 2023 | benzinga.com

Moore Kuehn Encourages ALBO, LPTX, ALR, and CEMI Investors to Contact Law Firm

February 2, 2023 | wsj.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Chembio Diagnostics, Inc. Buyout

February 1, 2023 | finance.yahoo.com

French Rapid Testing Company Scoops Up Chembio Diagnostics For $17M

January 31, 2023 | finance.yahoo.com

Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement

January 21, 2023 | seekingalpha.com

CEMI Chembio Diagnostics, Inc.

January 7, 2023 | forbes.com

Chembio Diagnostics

November 28, 2022 | finance.yahoo.com

Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System

November 6, 2022 | seekingalpha.com

Chembio Diagnostics, Inc. (CEMI) Q3 2022 Earnings Call Transcript

November 3, 2022 | finance.yahoo.com

Chembio Diagnostics Reports Third Quarter 2022 Financial Results

October 20, 2022 | finance.yahoo.com

Chembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022

September 6, 2022 | finance.yahoo.com

Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay

See More Headlines

Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CEMI
CUSIP: N/A
CIK: 1092662
Web: www.chembio.com
Phone: (631) 924-1135
Fax: 631-924-2065
Employees: 337
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,290,000.00
Net Margins: -47.03%
Pretax Margin: -46.96%
Return on Equity: -113.57%
Return on Assets: -38.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.23
Quick Ratio: 1.04

Sales & Book Value

Annual Sales: $48.34 million
Price / Sales: 0.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.48 per share
Price / Book: 0.95

Miscellaneous

Outstanding Shares: 36,726,000
Free Float: 35,514,000
Market Cap: $16.71 million
Optionable: Not Optionable
Beta: 1.85

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Richard L. Eberly
President, Chief Executive Officer & Director
Paul J. Angelico
Chief Operations Officer & Executive VP
Lawrence J. Steenvoorden
Chief Financial Officer, Secretary & Executive VP
Javan Esfandiari
Executive VP, Chief Science & Technology Officer
Atif Rizvi
Vice President-Finance

Key Competitors

View All Competitors

Insiders

CEMI Stock Analysis - Frequently Asked Questions

How were Chembio Diagnostics' earnings last quarter?: Chembio Diagnostics, Inc. (NASDAQ:CEMI) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.05. The company earned $12.06 million during the quarter. Chembio Diagnostics had a negative net margin of 47.03% and a negative trailing twelve-month return on equity of 113.57%. During the same quarter in the prior year, the company earned ($0.28) EPS.
What other stocks do shareholders of Chembio Diagnostics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), NovoCure (NVCR), Viper Energy (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and ReWalk Robotics (RWLK).

This page (NASDAQ:CEMI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Chembio Diagnostics (CEMI) Stock Price, News & Analysis

About Chembio Diagnostics Stock (NASDAQ:CEMI)

CEMI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

CEMI Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info